Abbott, Galapagos to develop rheumatoid arthritis therapy
As per the agreement, Abbott will make an initial upfront payment of $150m for rights related to the global collaboration. Upon successful completion of the RA Phase II
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.